SGEN Seattle Genetics, Inc.

67.04
+0  (1%)
Previous Close 66.57
Open 66.97
Price To book 14.93
Market Cap 9.55B
Shares 142,493,000
Volume 293,323
Short Ratio 11.71
Av. Daily Volume 757,423

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval announced August 19, 2011.
ADCETRIS
Hodgkin lymphoma and Anaplastic large cell lymphoma
Phase 1/2 clinical hold placed on December 27, 2016 was lifted March 6, 2017.
Vadastuximab Talirine (SGN-CD33A)
Myelodysplastic syndrome (MDS)
Phase 3 initiated May 2016. Enrollment ongoing as of February 2017.
Vadastuximab Talirine (CASCADE)
Acute myeloid leukemia (AML) - cancer
Phase 3 data due in 2017.
ADCETRIS in combination with chemotherapy ECHELON-1
Frontline Hodgkin lymphoma
Phase 2 trial initiated 3Q 2016.
SGN-CD19A
Frontline DLBCL cancer
Phase 3 enrollment completed November 2016. Data are due 2017 or 2018.
ADCETRIS in combination with chemotherapy - ECHELON-2
Frontline CD30-positive mature T-cell lymphomas - cancer
Approved August 17, 2015 under priority review.
ADCETRIS - AETHERA
Post-transplant Hodgkin lymphoma (HL) cancer
Phase 3 data released August 2016. sNDA to be filed mid 2017.
ADCETRIS
Cancer - ALCANZA trial for relapsed CD30-positive cutaneous T-cell lymphoma

Latest News

  1. Why Immunomedics, Inc. Got Hammered Today
  2. Seattle Genetics, Inc. breached its 50 day moving average in a Bullish Manner : SGEN-US : April 14, 2017
  3. Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter Financial Results on April 27, 2017
  4. New Strong Sell Stocks for April 3rd
  5. Seattle Genetics Presents Data Advancing Antibody-Drug Conjugate and Novel Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting
  6. Seattle Genetics Highlights Leadership in Antibody-Drug Conjugate Technology Innovation at the American Association for Cancer Research (AACR) Annual Meeting
  7. Battle in the Boardroom: What's Next for Immunomedics
  8. Why Shares of Immunomedics Inc Are up an Astounding 89% in 2017
  9. Seattle Genetics, Inc. breached its 50 day moving average in a Bullish Manner : SGEN-US : March 23, 2017
  10. Billionaires' Best Healthcare Stock Picks of 2017 (So Far)
  11. Take Advantage Of Donald Trump's Tweets To Buy Top Biotechs
  12. Seattle Genetics (SGEN) Up 8.2% Since Earnings Report: Can It Continue?
  13. INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm
  14. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Seattle Genetics Inc. of Class Action Lawsuit and Upcoming Deadline - SGEN
  15. Judge Blocks $2B Immunomedics-Seattle Genetics Deal (IMMU,SGEN)
  16. INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm
  17. March 13 Deadline Alert: Law Offices of Howard G. Smith Reminds Seattle Genetics, Inc. Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm
  18. DEADLINE MONDAY: Levi & Korsinsky, LLP Reminds Shareholders of Seattle Genetics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017 - SGEN
  19. Why Immunomedics, Inc. Jumped Higher Today
  20. Immunomedics (IMMU) Stock Soars After Deal with Seattle Genetics Is Halted